Skip to main content
Tulane Home Tulane Home

Clinical Trials

The Tulane Pulmonary Section is offering several clinical trials, registries and support groups available for patient participation. Currently there are trials open to enrollment for patients with idiopathic pulmonary fibrosis, cystic fibrosis, scleroderma, rheumatoid lung, and pulmonary hypertension due to interstitial lung disease. Some of the trials that are open for enrollment are listed below. Should you need additional information please contact: 

  • Sandy Ditta, Senior Research Administrator 504‐988‐4040 
  • Christine Glynn, RN/Clinical Research Coordinator 504‐988‐0743 
  • Kristen Lingle, RN/Clinical Research Coordinator 504‐988‐2325
     
Pulmonary Fibrosis

  • A Phase 3, randomized, double-blind, parallel-group, placebo- controlled multicenter study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis.
  • TRAIL1: A Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients With Rheumatoid Arthritis Interstitial Lung Disease
  • Pulmonary Fibrosis Foundation Patient Registry Protocol
  • Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF‐PRO) Registry
  • Pulmonary Fibrosis Support Group Meeting Second Wednesday of the Month 
Scleroderma

  • Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
  • A double-blind, randomized, placebo‐controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with Systemic Sclerosis associated Interstitial Lung Disease (SScILD)
  • GRASP‐Genome Research in African American Scleroderma Patients
Cystic Fibrosis

  • VX17-445-102: A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX 445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
  • VX17-445-103: A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del Mutation (F/F)
  • Cystic Fibrosis Patient Registry-source of searchable data in which all of our CF patients clinical, social, and demographic information is compiled and can by analyzed to further improve patient care